* ECDC survey shows rise in carbapenem resistance
* Problem most acute in southern Europe
* Health experts urge prudent drug use, more research
LONDON, Nov 15 (Reuters) - Europe faces a growing threat from superbugs that are resistant to a powerful, last-resort class of antibiotics known as carbapenems, the EU's disease monitoring agency said on Friday.
It is the latest in a series of warnings about antibiotic resistance from healthcare authorities around the world who fear that in future simple infections may no longer respond to medical treatment.
Overuse and misuse of antibiotics has fuelled a rise in drug-resistant infections and experts are particularly alarmed about bacteria that cannot be killed with carbapenems, the most powerful class of antibiotic drugs.
The proportion of infections resistant to carbapenems has increased sharply in the last four years - particularly in southern Europe - and almost all European countries now have reported cases, the European Centre for Diseases Prevention and Control (ECDC) said.
The most severe cases involve bloodstream infections, but drug-resistant bugs can also more frequently cause serious problems in the respiratory and urinary tracts.
The ECDC data showed that the proportion of bloodstream infections due to Klebsiella pneumoniae, a common cause of illness in hospital patients, that were resistant to carbapenems was above 5 percent in 2012 in five countries - Greece, Cyprus, Italy, Romania and Slovakia.
In 2009, only Greece and Cyprus exceeded that threshold.
And the ECDC said a new concern was the emergence of carbapenem-resistant Acinetobacter bacteria, which now represent more than 25 percent of infections in eight of 18 countries reporting data.
"Carbapenems are the last-line class of antibiotics, so the situation is really worrying," ECDC director Marc Sprenger said.
"Since 2009, it has become increasingly common for hospitals to be faced with treating patients that have carbapenem-resistant infections, often meaning that old and toxic drugs are used."
In addition to the need for more prudent use of antibiotics - including a greater awareness among the public that they cannot kill viruses - officials said there had to be more research into new antibiotics.
In recent years, there has been a rush for the exit by the drugs industry as its researchers have struggled to find leads for novel antimicrobial drugs. Companies have turned instead to more profitable lines of drug research, including treatments for cancer and chronic diseases.
Pfizer, once the leader in the field, closed its antibiotic research centre in Connecticut in 2011, to the dismay of many scientists. It now focuses anti-bacterial work on vaccines.
Others to have quit include Bristol-Myers Squibb and Eli Lilly, leaving only a handful of firms like GlaxoSmithKline and Merck & Co in the game.
Switzerland's Roche, however, has re-entered the arena through a $550 million tie-up with privately held Polyphor this month to develop and commercialise an experimental antibiotic against hospital superbugs.
Roche's initiative was welcomed by Maire Geoghegan-Quinn, European Commissioner for Research, Innovation and Science, speaking at a news conference that was webcast from Brussels on Friday.
"We need to find ways to use valuable antimicrobial drugs more wisely and to develop new drugs and treatments," she said, adding that an EU decision to provide funding to Polyphor under an antibiotic research project was vindicated by Roche's move.
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.